Emergent BioSolutions Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Emergent BioSolutions Inc Unternehmen

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Emergent BioSolutions Inc Informationen



BörsenkürzelEBS

Name des UnternehmensEmergent BioSolutions Inc

IPO-datumNov 15, 2006

CEOPapa (Joseph C)

Anzahl der mitarbeiter900

WertpapierartOrdinary Share

GeschäftsjahresendeNov 15

Addresse300 Professional Dr

StadtGAITHERSBURG

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl20879

Telefon12406313200

Websitehttps://emergentbiosolutions.com/

BörsenkürzelEBS

IPO-datumNov 15, 2006

CEOPapa (Joseph C)

Führungskräfte von Emergent BioSolutions Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

304.82K

+61.58%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

271.92K

+59.83%

Ms. Jessica Perl

Senior Vice President, General Counsel, Corporate Secretary

165.29K

+63.09%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

155.93K

+64.20%

Mr. William Hartzel

Senior Vice President - Manufacturing and Bioservices

146.77K

+68.21%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

116.59K

+85.86%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

114.67K

+22.10%

Mr. Ronald B. Richard

Independent Director

89.36K

+28.36%

Mr. Marvin L. White

Independent Director

79.44K

+31.90%

Mr. Keith A. Katkin, CPA

Independent Director

59.03K

+16.71%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

304.82K

+61.58%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

271.92K

+59.83%

Ms. Jessica Perl

Senior Vice President, General Counsel, Corporate Secretary

165.29K

+63.09%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

155.93K

+64.20%

Mr. William Hartzel

Senior Vice President - Manufacturing and Bioservices

146.77K

+68.21%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

116.59K

+85.86%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Commercial Product sales

223.30M

30.06%

MCM Product sales

156.50M

21.07%

Contracts and grants

36.70M

4.94%

Bioservices

23.40M

3.15%

Nach RegionUSD

Name

Umsatz

Anteil

Non-U.S Government

403.20M

54.27%

U.S.Government

36.70M

4.94%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Commercial Product sales

223.30M

30.06%

MCM Product sales

156.50M

21.07%

Contracts and grants

36.70M

4.94%

Bioservices

23.40M

3.15%

Aktionärsstatistik

Aktualisiert: Sun, May 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

7.60%

Dimensional Fund Advisors, L.P.

5.34%

State Street Investment Management (US)

5.23%

American Century Investment Management, Inc.

4.73%

Vanguard Capital Management, LLC

4.38%

Andere

72.72%

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

7.60%

Dimensional Fund Advisors, L.P.

5.34%

State Street Investment Management (US)

5.23%

American Century Investment Management, Inc.

4.73%

Vanguard Capital Management, LLC

4.38%

Andere

72.72%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

37.35%

Investment Advisor/Hedge Fund

31.07%

Hedge Fund

8.77%

Research Firm

3.93%

Individual Investor

3.86%

Pension Fund

1.01%

Bank and Trust

0.36%

Family Office

0.06%

Insurance Company

0.02%

Andere

13.55%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

412

42.30M

81.98%

-3.37M

2025Q4

378

39.86M

83.14%

+128.30K

2025Q3

417

39.73M

84.87%

+2.04M

2025Q2

439

37.58M

87.40%

+1.14M

2025Q1

454

36.44M

84.55%

-9.64M

2024Q4

461

35.04M

82.31%

+2.84M

2024Q3

467

32.21M

81.37%

+1.29M

2024Q2

485

30.86M

99.60%

-5.54M

2024Q1

494

36.44M

103.37%

-17.72M

2023Q4

512

41.89M

103.68%

-1.06M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

3.92M

7.6%

+17.75K

+0.45%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

2.25M

4.36%

+112.27K

+5.25%

Dec 31, 2025

State Street Investment Management (US)

2.70M

5.22%

+250.62K

+10.25%

Dec 31, 2025

American Century Investment Management, Inc.

2.44M

4.72%

+57.06K

+2.40%

Dec 31, 2025

Charles Schwab Investment Management, Inc.

1.62M

3.13%

+237.15K

+17.16%

Dec 31, 2025

Palisade Capital Management, LLC

1.27M

2.45%

-160.25K

-11.24%

Dec 31, 2025

Geode Capital Management, L.L.C.

1.25M

2.42%

-28.68K

-2.24%

Dec 31, 2025

Oak Hill Advisors, L.P.

1.11M

2.16%

--

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

AdvisorShares Insider Advantage ETF

0.97%

Royce Quant Small-Cap Quality Value ETF

0.41%

State Street SPDR S&P Biotech ETF

0.28%

Federated Hermes MDT Small Cap Core ETF

0.23%

Harbor Human Capital Factor US Small Cap ETF

0.19%

Direxion Daily S&P Biotech Bull 3X Shares

0.18%

Pacer US Small Cap Cash Cows ETF

0.16%

Invesco RAFI US 1500 Small-Mid ETF

0.15%

Avantis US Small Cap Value ETF

0.14%

iShares Micro-Cap ETF

0.13%

AdvisorShares Insider Advantage ETF

Anteil0.97%

Royce Quant Small-Cap Quality Value ETF

Anteil0.41%

State Street SPDR S&P Biotech ETF

Anteil0.28%

Federated Hermes MDT Small Cap Core ETF

Anteil0.23%

Harbor Human Capital Factor US Small Cap ETF

Anteil0.19%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.18%

Pacer US Small Cap Cash Cows ETF

Anteil0.16%

Invesco RAFI US 1500 Small-Mid ETF

Anteil0.15%

Avantis US Small Cap Value ETF

Anteil0.14%

iShares Micro-Cap ETF

Anteil0.13%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten